Rentosertib and proteomic aging clocks in idiopathic pulmonary fibrosis: an exploratory substudy
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedThe description presents a small exploratory proteomic substudy of a phase 2a trial in people with idiopathic pulmonary fibrosis, examining how treatment with the experimental drug Rentosertib related to proteomic aging clocks. The creator stresses this is not proof that Rentosertib reverses human aging. [1]
The discussed data come from a small exploratory proteomic substudy of a clinical phase 2a trial in people with idiopathic pulmonary fibrosis. [1]
Proteomic aging clocks attempt to estimate biological age or age-related changes from certain protein patterns in the blood. [1]
The creator states the results are not proof that Rentosertib reverses aging in humans. [1]
Rentosertib tested in idiopathic pulmonary fibrosis
According to the description, Rentosertib is an experimental drug currently being studied, among other things, in idiopathic pulmonary fibrosis. The data discussed come from a small exploratory proteomic substudy of a clinical phase 2a trial. The creator notes that the results do not mean Rentosertib has been shown to 'rejuvenate' people. [1]
What proteomic aging clocks aim to estimate
The description explains that proteomic aging clocks try to estimate biological age or age-related changes from certain protein patterns in the blood. It also distinguishes biological age from the age on an identity card. The video is said to cover what these clocks measure and what was actually observed in the phase 2a study. [1]
Creator urges caution with anti-aging headlines
The creator says the findings are exciting but do not show that Rentosertib rejuvenates humans, and calls for close scrutiny of spectacular anti-aging headlines. The description states the data are no proof that Rentosertib reverses aging in humans. It also notes the drug is experimental and the results are no recommendation for use. [1]
Context & limits
This is based only on the video description; the video and transcript were not reviewed. The description gives no sample size, follow-up, comparator details or numerical results, and the substudy is described as small and exploratory.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
kleinen explorativen Proteom-Substudie einer klinischen Phase-2a-Studie
anhand bestimmter Proteinmuster im Blut biologisches Alter
kein Nachweis dafür, dass Rentosertib das Altern
About this video
Creator description · original textText language: German
longevityuta · 9 min · Source published: 2026-10-11
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.